Havn Life Applies for License to Produce and Sell Psilocybin

Ryan Allway

October 19th, 2020


Havn Life Sciences Inc. (CSE:HAVN) (FSE:5NP) (the “Company” or “Havn Life”), a biotechnology company focused on unlocking human potential using evidence-informed research and developing standardized psychoactive compounds derived from plants and fungi, is pleased to announce it has submitted an application to Health Canada to obtain a Controlled Drugs and Substances Dealer’s Licence (“Licence”) for Psilocybin and Psilocin.

This Licence, when issued, will permit Havn Life to sell naturally-derived psilocybe spp compounds, under the Controlled Drug and Substances Act, to universities, researchers and companies.

“Helping researchers unlock the benefits of natural medicines is the first step that must be taken to move this industry forward,” said Alexzander Samuelsson, Chief Research Officer of Havn Life. “This is an entirely new industry that is being built from the ground up and the potential natural medicines have only begun to be explored. We are committed to playing a key role in this emerging field of research once we have earned our license to sell naturally-derived psilocybin in Canada.”

“Psychedelics have been used as a medicine for centuries, but there is still so much work to do to bring these treatments to the masses,” said Dr. Ivan Casselman, Chief Psychedelic Officer of Havn Life. “We are committed to developing safe, quality controlled, naturally derived products from Psilocybe spp. mushrooms. With the Controlled Drugs and Substances Dealer’s Licence we will have the ability to develop a standardized, quality-controlled supply chain of psychedelic substances for use by researchers, universities and companies.”

Earlier this year, Havn Live was granted a Section 56 exemption from Health Canada to begin work with psilocybin. The Section 56 exemption licence grants Havn Life the ability to possess psilocybin for research purposes, specifically for the development of quality control methods.

On Behalf of The Board of Directors

Susan Chapelle & Tim Moore

About Havn Life Sciences Inc.

Havn Life Sciences is a biotechnology company on a mission to unlock human potential using evidence-informed research. The Company is focused on standardized, quality-controlled extraction of psychoactive compounds from plants and fungi, and the development of natural health care products from non-regulated compounds. Learn more at: havnlife.com and follow us on Facebook, Twitter and Instagram.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Latest posts